Advances in genetic analysis are revolutionizing the practice of medicine, improving patient care, enabling early disease detection, and advancing the treatment of diseases. Novel assays, based on state of the art gene expression analyses, are being developed to improve disease detection and diagnosis across therapeutic areas.
Contact us to explore how DermTech’s patented platform technology can advance your compounds through the clinical stages of development.
Current indications include:
Basal Cell Carcinoma
Cutaneous T-cell Lymphoma
Squamous Cell Carcinoma
DermTech provides Medimmune access to its non-invasive, adhesive patch gene expression platform to support the development of drug candidates for inflammatory skin conditions.
DermTech provides Biogen access to its non-invasive, adhesive patch gene expression platform to support the development of a novel drug candidate addressing an inflammatory condition of the skin. Successful completion of the initial clinical testing has led to expansion of the initial collaboration and an extension of the collaboration to additional disease indications.